Top Tweets for #MONARCH3
Also true in breast oncology. #MONARCH3 trial of 1L ET+/-abema for metastatic breast cancer. Doubling of PFS, major numerical OS benefit with abema— yet with a clear crossing of the curves. Important to recognize frail patients, which may do well (if not better) with monotherapy.
Same phenomenon occurs in #MARIPOSA as noted by Dr. @harpreet_md in #FLAURA2 - its minor but perhaps early increase toxicity with intensified treatment is bad for some patients outcome? #WCLC2025 #lcsm
やっぱりTHIE AUDIOはあたたかい。
凄くクリアで解像度高いのに音の繋がりが滑らかでぬくぬく。
低音域は主張しすぎておらず全然支配的ではないのにも関わらず、分離と解像度のお陰でベースの弦の揺れまで聴き取れる。
高音域も伸びる伸びるで聴いてて楽しい。
#THIEAUDIO #Monarch3
MONARCH 3 final OS results.
Statistically negative (p=0.06), but hard to argue that 13.1 months delta in OS does not denote a clinical benefit.
https://t.co/iO1fsYJOEh
#SABCS23 Highlights w/ @hoperugo on HR+ #breastcancer
- #NATALEE
- #MONARCH3
- #INAVO120
- #TB01
Full discussion:
- https://t.co/jZrRZsOfeq
- https://t.co/ovqFoUtlwT
- Also on “Oncology Brothers” podcast
#MedTwitter #OncTwitter #bcsm @SABCSSanAntonio @TargetedOnc
Looking for updates from #SABCS23? Watch as Dr. @JAMouabbi of the #OncData Editorial Board and @MDAndersonNews shares a summary of the key #HER2CLIMB02, #MONARCH3, and #INAVO trials and their potentials to impact the field!
https://t.co/GnOot48o33
#bcsm #SABCS @SABCSSanAntonio
#SABCS23 | Quale valore assumono i nuovi dati del #MONARCH3 rispetto alla domanda clinica e nella storia della patologia? Lo abbiamo chiesto ad @ALEDIGNUS12.
@UniAvogadro https://t.co/a5tzSkhz9A
#SABCS23 in pillole, secondo @ArmandOrlandi
#breastcancer @matteolambe @BianchiniGP #MONARCH3 #NATALEE #monarchE #INAVO120
#SABCS2023 left many of us with hope, optimism but many unanswered questions and controversies! Our podcast covers the 4 following pivotal trial updates
#MONARCH3
#INAVO120
#KATHERINE
#PREFERABLE-EFFECT
https://t.co/C6ki1jRHIb
#SABCS23 | Lucia Del Mastro: dal #MONARCH3 conferme su efficacia e impatto clinico dell’impiego di abemaciclib nella paziente con #carcinomamammario HR+, HER2-
A breve l’intervista completa 🔜!
@matteolambe @SanMartino_Ge
Read more daily breast cancer research updates from #SABCS23 here: https://t.co/ASNLR12BhA.
#breastcancerresearch #breastcancer #Verzenio #MONARCH3
2. #MONARCH3 8 year follow-up: #Abemaciclib + AI vs AI in HR+ mBC 1L:
- ITT showed ⬆️of 13.1mos OS with Abema (66.8 vs 53.7 mos) BUT⛔️ statistical significant (HR: 0.804; 95% CI, 0.637-1.015; p=0.0664) 🤔 Now what?
- Ribo > Abema > Palbo?
3/6
MONARCH3: Final OS analysis (median fu 8 years)
66.8 vs 53.7 months
Not statistically significant but clinically meaningful 🔺13.1 months
#bcsm #SABCS23 @OncoAlert
#SABCS23 Day 2 Highlights #CommunityOnc:
HR+
1. Update #CM7FL + #KN756
2. #MONARCH3
3. #HER2CLIMB02 (Her2+)
4. Role of Anthracyclines
5. #OLAnzaPiNE (all solid tumors)
1/6
#bcsm #OncTwitter @SABCSSanAntonio @AACR @UTHealthSAMDA #BreastCancer #MedTwitter @ThanksCancer
#MONARCH3 Final OS data (median follow up of 8.1 years)
OS: 66.8 vs 53.7 months
Was not statistically significant even
with 13.1 months 🔺 different! To control Arm clinical meaningful improvement ✔️
Is it because of small sample size? 2 ndry endpoint?
@OncoAlert #SABCS23
Final analysis of #MONARCH3 trial in patients with advanced endocrine sensitive #BreastCancer: > 1 year OS gain with addition of #abemaciclib to ET but not statistically significant…great to see median OS beyond 5 years also in visceral disease
@OncoAlert #bcsm @SABCSSanAntonio
#MONARCH3 trial
1st line abemaciclib in HR+/HER2- aBC
Clinically and numerically higher OS 66.8 vs 53.7 months
#SABCS23 #abemaciclib
@SABCSSanAntonio
Il #Monarch3 è uno tra i più importanti studi che hanno valutato l’efficacia dei CDK 4/6 inhibitor in un setting di tumore della mammella con recettori ormonali positivi HER2- endocrino sensibili. #breastcancer
Ce ne parla @BianchiniGP.
🎙️https://t.co/DvTyuxVBMp
Auch in unserem Live-#Webinar am morgigen Dienstag 20.9. um 17:30 Uhr ist die #MONARCH3-Studie eines der #ESMO22-Highlights von @DLueftner zum #Mammakarzinom. Jetzt anmelden und einen CME-Punkt sammeln: https://t.co/Q91SVInLDE
ASCO [2022] Breast Cancer In-Depth Slides: MOASC @kayyeung
@UCSDHealth @UCSDCRCERA @MOASC_Office #OncoTwitter #DESTINYBreast04 #TROPiCS02 #PALOMA2 #MONARCH3 #KEYNOTE522
https://t.co/ShHmBe0PQe
![oncologytube's tweet photo. ASCO [2022] Breast Cancer In-Depth Slides: MOASC @kayyeung
@UCSDHealth @UCSDCRCERA @MOASC_Office #OncoTwitter #DESTINYBreast04 #TROPiCS02 #PALOMA2 #MONARCH3 #KEYNOTE522
https://t.co/ShHmBe0PQe https://t.co/2FejnlwOdq](https://pbs.twimg.com/media/Fct4L3hXEAAa4WV.jpg)
We also saw results of #Monarch3 (AI +/- Abemaciclib for HR+MBC). While OS data showed a 14.4-month difference (54.4 to 67.1 mons) the p value was NOT statistically significant, but a final OS report is pending (2023). (Qs next tweet...) #CancerCoffeeConversation #ESMO22 3/
Last Seen Hashtags on Sotwe
Olympic_City
Seen from United States
apola_trajectory
Seen from United States
男娘
Seen from Italy
روتينhd_انتساب_العربي
Seen from Egypt
prelemi
Seen from Italy
picoftheday
Seen from United States
Buntelligence
Seen from United States
bnwo castration
Seen from Ukraine
伪娘露出
Seen from Italy
BaitStraight
Seen from United Kingdom
Trends for you
Most Popular Users
Elon Musk 
@elonmusk
240.2M followers
Barack Obama
@barackobama
119.3M followers
Donald J. Trump
@realdonaldtrump
111.6M followers
Cristiano Ronaldo
@cristiano
109.3M followers
Narendra Modi
@narendramodi
106.9M followers
Rihanna
@rihanna
97.4M followers
NASA
@nasa
92.1M followers
Justin Bieber
@justinbieber
90.6M followers
KATY PERRY
@katyperry
87M followers
Taylor Swift
@taylorswift13
80.8M followers
Lady Gaga
@ladygaga
72.4M followers
Kim Kardashian
@kimkardashian
69.5M followers
Virat Kohli
@imvkohli
68.9M followers
YouTube
@youtube
68.6M followers
Bill Gates
@billgates
63.5M followers
The Ellen Show
@theellenshow
62.5M followers
CNN
@cnn
61.9M followers
Neymar Jr
@neymarjr
61.5M followers
X
@x
60.9M followers
Selena Gomez
@selenagomez
60.1M followers